# Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

> **NCT02983799** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 272 (actual)

## Conditions studied

- Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

## Interventions

- **DRUG:** OLAPARIB

## Key facts

- **NCT ID:** NCT02983799
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-22
- **Primary completion:** 2020-12-03
- **Final completion:** 2020-12-03
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2022-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02983799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02983799, "Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02983799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*